Evaxion Biotech raised $10.8 million through a recent public offering of nearly 4 million ADSs. The offering includes warrants for investors to buy up to 50% more ADSs at $2.71…
Aurion Biotech plans to IPO on the New York Stock Exchange under the ticker "AURN." Challenges include a lawsuit from Alcon Research alleging violations of shareholder rights. Aurion countersued, accusing…
Investing in Biotech: The XBI Opportunity The SPDR S&P Biotech ETF, known by its ticker XBI, stands out as a prime investment vehicle within the U.S. biotechnology landscape. Managed by…
Ascentage Pharma, a key player in the global pharmaceutical landscape, has recently secured an impressive $126.4 million through a U.S. IPO. This substantial funding is primarily earmarked for the advanced…
**Investment firm RTW Investments has launched a cutting-edge biotech venture named Prolium Bioscience, aimed at revolutionizing treatment for certain cancers.** With a strategic focus on a promising CD20×CD3 bispecific antibody,…
### Major Startup Funding Highlights This Week Investors are making waves in the startup ecosystem as 2024 starts off strong with significant funding rounds. This week continues to showcase major…
Evaxion Trajectory Shift Evaxion Biotech (NASDAQ: EVAX) has just implemented a significant change to its American Depositary Shares (ADS) ratio, set in motion from January 14, 2025. Previously, each ADS…
Italian VC XGEN Venture Leads the Charge XGEN Venture, an innovative European venture capital firm, has officially launched its inaugural fund with a substantial capital commitment of **€180 million** (approximately…
Dimension Ventures is making headlines as it embarks on an ambitious journey, setting out to raise $500 million for its second fund in under two years. This initiative is focused…
Haverhill, Massachusetts, is setting its sights on the future with an impressive new initiative. The city government is eager to tap into significant state funding recently established to boost sectors…